DNA/RNA Methylation-Driven Coronary Microvascular Dysfunction: Emerging Pathogenic Mechanisms and Therapeutic Opportunities for Heart Failure in Diabetes
Open Access
- 11 July 2026
- journal article
- review article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (6) , 2435-2450
Abstract
Coronary microvascular dysfunction (CMD) is an established pathological driver of heart failure, with endothelial cell (EC) dysfunction representing a central determinant of its development and progression. EC impairment disrupts normal coronary microvascular tone and perfusion, and promotes myocardial inflammation, fibrosis, and cardiomyocyte stress, as characteristic features of the diabetic heart. CMD is often clinically silent and undiagnosed, whilst conventional therapies targeting cardiometabolic risk factors are largely ineffective towards restoring microvascular integrity. Emerging evidence implicates epigenetic dysregulation, including DNA and RNA methylation, as a critical mechanism underlying maladaptive EC signalling. These key modifications encode microvascular memory, sustaining endothelial dysfunction even after risk factors are optimally controlled; DNA methylation stabilises pathogenic transcription whilst RNA methylation regulates transcript stability and translation to support continued disruption of EC homeostasis. Indeed, preclinical studies demonstrate that pharmacological DNA methylation inhibitors and RNA methylation modulators can restore healthy EC function, reflected by reduced inflammation and preserved microvascular integrity, positioning such epigenetic pathways as central determinants of CMD with clear mechanistic relevance and therapeutic potential. Selective methylation targeting therefore offers exciting translational promise to reprogram dysfunctional ECs in diabetic patients, reversing CMD and preventing development and progression of associated heart failure. This timely review summarises current knowledge of EC epigenetic regulation, focusing on methylation modifications, and explores how emerging mechanistic insights may be leveraged to advance therapeutic targeting of CMD in the diabetic heart as foundation for development of innovative clinical management strategies.Keywords
Funding Information
- British Heart Foundation (FS/PhD/24/29562)
This publication has 124 references indexed in Scilit:
- Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic OpportunitiesMedcomm, 2026
- METTL3-mediated m6A methylation: implications for diabetes pathogenesis and therapeutic potentialMolecular Biology Reports, 2025
- Molecular Interplay of Gene Network Dynamics, Epigenetic Regulation, and Therapeutic Mapping in Cardiovascular DiseaseCardiovascular Drugs and Therapy, 2025
- Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical ImplicationsCardiovascular Drugs and Therapy, 2025
- DNMT1 prolonged absence is a tunable cellular stress that triggers cell proliferation arrest to protect from major DNA methylation lossCellular and Molecular Life Sciences, 2024
- Coronary Microvascular Dysfunction: What Clinicians and Investigators Should KnowCurrent Atherosclerosis Reports, 2023
- Increased m6A-RNA methylation and FTO suppression is associated with myocardial inflammation and dysfunction during endotoxemia in miceMolecular and Cellular Biochemistry, 2021
- New insight in molecular mechanisms regulating SIRT6 expression in diabetes: Hyperglycaemia effects on SIRT6 DNA methylationJournal of Cellular Physiology, 2020
- Epigenetic Regulation of Endothelial Cell Function by Nucleic Acid Methylation in Cardiac Homeostasis and DiseaseCardiovascular Drugs and Therapy, 2020
- Genomic imprinting and its effects on postnatal growth and adult metabolismCellular and Molecular Life Sciences, 2019